Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention

Journal of the National Cancer Institute

Volumn 95, Issue 7, 2003, Pages 526-532

  Freedman, Andrew N ^a   Graubard, Barry I ^a   Rao, Sowmya R ^a   McCaskill Stevens, Worta ^a   Ballard Barbash, Rachel ^a   Gail, Mitchell H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RISK; CAUCASIAN; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG INDICATION; DRUG USE; ENDOMETRIUM CANCER; FEMALE; FOOD AND DRUG ADMINISTRATION; FREQUENCY ANALYSIS; GENDER; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; NEGRO; PATIENT SELECTION; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; UNITED STATES; AFRICAN AMERICAN; BREAST TUMOR; CONFIDENCE INTERVAL; CROSS-SECTIONAL STUDY; HISPANIC; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PRESCRIPTION; QUESTIONNAIRE; RISK FACTOR; STATISTICS;

ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; ELIGIBILITY DETERMINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; MIDDLE AGED; PRESCRIPTIONS, DRUG; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0037414209     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.7.526     Document Type: Article

References (19)

1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: a report of the National Surgical Adjuvant Breast and Bowel Project P-1. J Natl Cancer Inst 1998;90:1371-88.
2. Fisher B. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial: a reflective commentary. J Clin Oncol 1999;17:1632-9.
3. Rockhill B, Colditz G, Kaye J. Re: tamoxifen prevention of breast cancer: an instance of the fingerpost. J Natl Cancer Inst 2000;92:657-8.
4. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-46.
5. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001;93:358-66.
6. National Center for Health Statistics. National Health Interview Survey (NHIS). Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. [Last accessed July 22, 2002.] Available at: http://www.cdc.gov/NCHS/nhis.htm.
7. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81:1879-86.
8. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541-8.
9. Anderson SJ, Ahnn S, Duff K. NSABP breast cancer prevention trial risk assessment program, Version 2. NSABP Biostatistical Center Technical Report. Pittsburgh (PA): Department of Biostatistics, University of Pittsburgh; August 14, 1992.
10. Botman SL, Moore TF, Moriarity CL, Parsons VL. Design and estimation for the National Health Interview Survey, 1995-2004. National Center for Health Statistics. Natl Vital Stat Rep 2000; p. 1-31.
11. Korn EL, Graubard BI. Analysis of health surveys. Sec. 3.2. New York (NY): John Wiley & Sons; 1999. p. 22-8, 64-8.
12. Shah BV, Barnwell BG, Bieler GS. SUDAAN user's manual, release 8.0. Research Triangle Park (NC): Research Triangle Institute; 1997.
13. SAS Institute Inc. SAS/STAT user's guide, version 8. Cary (NC); 1999.
14. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus-progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
15. Newman LA, Rockhill B, Bondy ML, Abrams J, Berlin JA, Colditz GA, et al. Validation of the Gail breast cancer risk assessment model in African American women based on a multi-center case-control study of 3,283 African American and 5,974 white American women [abstract 976]. Proc ASCO 2002;21:245A.
16. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998;352:98-101.
17. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93-7.
18. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817-24.
19. Taylor AL, Adams-Campbell LL, Wright JT Jr. Risk/benefit assessment of tamoxifen to prevent breast cancer? Still a work in progress. J Natl Cancer Inst 1999;91:1792-3.